Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10%, with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma In Situ.","authors":"Mark S Nestor, Aysham Chaudry, Robert J Vanaria, Wilhelmina Lam, Alexandra Devries, Alec Lawson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous squamous cell carcinoma in situ (isSCC) is a common skin cancer often arising on the face. Standard care involves excision or destruction, but less invasive therapies are becoming increasingly explored. Aminolevulinic acid photodynamic therapy (ALA-PDT) with red light has shown potential for treating isSCC. This study assesses the safety, tolerability, and efficacy of ALA-PDT with red light for facial isSCC.</p><p><strong>Methods: </strong>Twenty patients with biopsy-confirmed facial isSCC (0.4-1.3cm) were treated. Lesions were prepared with a 4×4 gauze, followed by application of ALA gel 10% with 3-hour incubation. Red light therapy (13 minutes and 30 seconds; 37J/cm²) was then administered. Patients received two sessions 28±3 days apart. Eight weeks after the second treatment, lesions were excised for histopathologic analysis. The primary endpoint was complete histologic clearance, with clinical clearance as a secondary endpoint. Safety was evaluated through adverse events (AEs), local skin reactions (LSRs), and treatment-site pain.</p><p><strong>Results: </strong>All 20 patients completed the study. Complete histologic clearance was achieved, and complete clinical clearance was observed in 100% (20 of 20) patients. No treatment-related AEs occurred. One unrelated case of contact dermatitis was reported. The most common LSR was moderate erythema, peaking after treatment and resolving over time. Mild scaling was also observed with similar resolution. Median posttreatment pain scores were 0 (range: 0-3) after ALA application and 3.5 (range: 0-10) after red light therapy.</p><p><strong>Conclusion: </strong>ALA-PDT with 10% gel and red light demonstrated excellent efficacy, safety, and tolerability, supporting its role as a promising noninvasive treatment for facial isSCC.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"50-54"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clearance of Cutaneous Lichen Planus with Deucravacitinib.","authors":"Kyle Machynia, Jason E Hawkes","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lichen planus (LP) is an idiopathic, immune-mediated inflammatory disorder commonly characterized by pruritic, violaceous papules and plaques that often involve the extremities. Although a variety of topical and systemic therapies are used, no targeted treatments are currently approved by the US Food and Drug Administration for this indication, and management of refractory disease remains challenging. Tyrosine kinase 2 (TYK2) inhibitors selectively modulate several cytokine signaling pathways, including interleukin (IL)-12, IL-23/IL-17, and type I interferon signaling, which are implicated in the pathogenesis of LP. Here, we report a case of biopsy-confirmed, treatment-refractory, cutaneous LP that achieved near-complete resolution after 2 months of therapy with the oral TYK2 inhibitor, deucravacitinib.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"47-49"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated Hand Involvement as the Presenting Sign of Dermatitis Herpetiformis.","authors":"Zane Sejdiu, Romina Garakani, Stephen Ansah-Addo, Kelly McCoy, Farhaan Hafeez, Andrew C Krakowski","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Dermatitis herpetiformis (DH) is an autoimmune blistering disease associated with celiac disease, classically presenting as intensely pruritic erythematous vesicles and papules on the elbows, knees, buttocks, and scalp. Involvement of the dorsal hands is extremely rare, complicating diagnosis. We report a unique case of DH confined solely to the dorsal hands in a 68-year-old woman with a five-year history of recurrent, pruritic vesicles initially misdiagnosed as hand eczema. Direct immunofluorescence confirmed the diagnosis of DH with granular immunoglobulin (Ig) A deposition along the dermo-epidermal junction, and serologic testing revealed elevated tissue transglutaminase IgA. This case highlights an uncommon presentation of DH and emphasizes the need to consider it in chronic, unexplained dorsal hand eruptions to prevent misdiagnosis and delayed treatment.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"55-57"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.","authors":"Joshua K Morales, Jennifer Keelin, Toan N Vu, Sabrina C Camacho, Selene M Kizy, Sarah Kazemeini, Rebecca Metellus, Naif Hebo, David G Cotter","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for type 2 diabetes and obesity, have demonstrated potential anti-inflammatory and immunomodulatory effects that may be beneficial in chronic inflammatory skin conditions such as psoriasis and hidradenitis suppurativa (HS). A systematic review of the literature was conducted, focusing on prospective studies, case reports, and systematic reviews that evaluated the impact of GLP-1 RAs on these diseases. In psoriasis, GLP-1 RAs, particularly liraglutide, have been associated with improvements in the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), especially among patients with T2D. Reported benefits include enhanced glycemic control, weight reduction, and decreased levels of inflammatory markers, suggesting that GLP-1 RAs may modulate immune pathways and proinflammatory cytokine activity involved in the pathogenesis of psoriasis. Similarly, in HS, GLP-1 RAs such as liraglutide and semaglutide have shown promising results, including decreased lesion severity, improved quality of life, and reduced systemic inflammation. Weight loss induced by these agents may also contribute to symptom improvement by reducing mechanical stress in intertriginous areas and mitigating inflammatory responses associated with HS. Although preliminary evidence suggests that GLP-1 RAs may play a role in managing psoriasis and HS through both metabolic and immunologic mechanisms, current data are limited to early-phase studies and case reports. Further large-scale randomized controlled trials, some of which are ongoing, with diverse study populations are necessary to better understand their efficacy, safety, and long-term impact in the treatment of these chronic inflammatory skin conditions.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"26-32"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into Tanning Biology and Tanning Products.","authors":"Gabriella Resnick, Megan Khajeh-Afzaly, Faraz Yousefian, Abbas Raza, Naiem T Issa","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review aims to critically assess the literature on the mechanisms of action, clinical uses, formulation strategies, and adverse effects of self-tanning agents, with a focus on dihydroxyacetone (DHA), melanotan, forskolin, and carotenoids.</p><p><strong>Methods: </strong>A systematic literature review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were screened for relevance to the mechanisms of action, clinical applications, chemical formulations, or adverse effects of self-tanning molecules. A total of 68 peer-reviewed studies were included.</p><p><strong>Results: </strong>DHA induces pigmentation via the Maillard reaction and has demonstrated additional dermatologic applications, including use in vitiligo and erythropoietic protoporphyria and as a potential topical antifungal. Concerns persist about DHA-related cytotoxicity, genotoxicity, and systemic absorption. Unregulated melanotan I and II use has caused serious adverse effects, including rhabdomyolysis, renal infarction, and priapism. While forskolin stimulates melanin production independently of melanocortin receptors and has demonstrated efficacy in animal models, carotenoids, when ingested orally, accumulate in skin and subcutaneous fat, creating a yellow-orange hue. Both agents remain underresearched in human populations.</p><p><strong>Limitations: </strong>Limitations include lack of standardized reporting across included studies, variability in study outcomes, and limited long-term safety data.</p><p><strong>Conclusion: </strong>Sunless tanning agents offer UV-free alternatives for cosmetic pigmentation but are not without risk. While DHA and melanotan remain the dominant agents in current use, forskolin and carotenoids offer alternative pathways for pigmentation and photoprotection. Further clinical studies are necessary to evaluate long-term safety, efficacy across skin types, and formulation optimization. Regulatory frameworks and dermatologic guidance must evolve to reflect the expanding landscape of sunless tanning modalities.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"33-42"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Transient \"Blueberry Muffin\" Rash in a Neonate with Acute Myeloid Leukemia: A Case Report and Review of the Literature.","authors":"Aaron Cheng, Justin Guzman, David G Cotter","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A \"blueberry muffin rash,\" typically attributed to congenital toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus (TORCH) infections, is a rare and underreported cutaneous manifestation of serious underlying pathology, including hematologic malignancies. We report a case of congenital acute myeloid leukemia (AML) in a full-term newborn who presented at day-of-life 0 with multiple blue to purple macules, patches, and indurated papulonodules and plaques on the trunk and extremities consistent with a \"blueberry muffin rash\". Notably, the rash was transient and spontaneously resolved within 24 hours of life, making it easy to overlook, potentially delaying life-saving treatment. This case reinforces the need for a full diagnostic workup and high clinical suspicion for leukemia in neonates presenting with a \"blueberry muffin rash.\"</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"22-25"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-Derived Extracellular Vesicles in Dermatology: A Review of Emerging Therapeutic Applications.","authors":"Joshua Burshtein, Jason Wei, Lidia Majewska, Todd Schlesinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This article aims to evaluate and discuss the therapeutic potential of plant-derived extracellular vesicles (PEVs) in clinical and aesthetic dermatology by examining their mechanisms, clinical application, efficacy, and safety profiles.</p><p><strong>Methods: </strong>A comprehensive literature search was completed using the keywords \"plant-derived exosomes,\" \"dermatology,\" \"skin disorders,\" \"treatment,\" \"inflammatory skin conditions,\" \"cosmetic,\" \"regenerative medicine,\" \"wound healing,\" and \"chemotherapeutic skin-related toxicities.\" The authors reviewed all studies and included those that addressed PEVs.</p><p><strong>Results: </strong>PEVs demonstrate multifaceted therapeutic properties: (1) immunomodulation through suppression of proinflammatory cytokines (interleukin 17, tumor necrosis factor-α), (2) restoration of skin barrier function, (3) promotion of tissue regeneration in wounds and scars, and (4) effective stabilization and delivery of therapeutic cargo (microRNAs, hydrophobic drugs). Clinical case studies, particularly with rose stem cell exosomes, show efficacy in atopic dermatitis, psoriasis, wound healing, and chemotherapy-induced dermatologic toxicities, with rapid symptom relief and structural improvement.</p><p><strong>Limitations: </strong>Current evidence is constrained by predominance of preclinical data focused primarily on mammalian-derived exosomes as well as variability in PEV isolation and characterization methods across studies. Clinical data regarding the use of PEVs remains limited in the literature.</p><p><strong>Conclusion: </strong>PEVs represent a promising new class of dermatologic therapeutics combining plant-derived biocompatibility with targeted therapeutic effects. Future research should prioritize controlled clinical trials, standardization of production methods, and exploration of engineered PEVs for precision medicine applications in dermatology.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism Risk in Patients with Atopic Dermatitis Treated with Abrocitinib: A Review of Female Patients on Oral Contraception and Nicotine Exposure From the JADE Clinical Trial Program.","authors":"Diego Ruiz Dasilva, Graham H Litchman, Alondra Soto-González, Naiem Issa, E James Song, Christopher G Bunick, James Q Del Rosso","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Oral Janus kinase inhibitors (JAKi) are effective in managing moderate-to-severe atopic dermatitis (AD), but concerns regarding venous thromboembolism (VTE) risk persist, particularly in female patients with overlapping risk factors such as oral contraceptive pill (OCP) use and nicotine exposure (primarily smoking). We evaluated VTE events in this population using data from the abrocitinib clinical trial program.</p><p><strong>Methods: </strong>We reviewed the Phase II and Phase III clinical trial data (JADE program) for abrocitinib in AD, focusing on VTE incidence in female patients with documented OCP use and nicotine exposure to contextualize thromboembolic risk.</p><p><strong>Results: </strong>VTE events were rare. Nonfatal VTE incidence was low, with dose-specific incidence rates less than 1.0 per 100 patient-years (PY). Among female patients taking OCPs and current or former smokers, no VTEs occurred (0 of 78). In the overall active study group, most VTEs arose in patients with multiple baseline risk factors (eg, obesity, immobilization, prior thrombosis). Discontinuation due to VTE-related adverse events was infrequent (n=7, 0.13/100 PY) in the overall study group. No VTE-related deaths were reported. Comparative rates were consistent with or lower than background risk in AD populations with similar demographics.</p><p><strong>Limitations: </strong>This review is limited by the lack of publicly available patient-level data, possible underreporting of lifestyle risk factors, inability to quantify total nicotine exposure, small sample size, and unmeasured confounding variables.</p><p><strong>Conclusion: </strong>VTE events in female patients with AD treated with abrocitinib, including those taking OCPs and with nicotine exposure, were rare and generally associated with multiple concurrent risk factors for VTE. No VTE events were noted in female patients treated with abrocitinib who were taking OCPs and with history of smoking/nicotine exposure. These findings may help contextualize VTE risk in real-world treatment decisions.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 1","pages":"7-10"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Skincare to Skin Fitness: A Performance Framework for Dermatologic Practice.","authors":"Rachel Cohen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Preventive medicine has become the foundation of modern healthcare, emphasizing early intervention and lifestyle modification to avert disease and promote longevity. Despite this paradigm shift, dermatology remains largely episodic, focused on treating visible pathology rather than conditioning the skin for resilience and disease prevention. This article introduces the concept of skin fitness, a structured, proactive model that applies the principles of physical training-progression, consistency, and recovery-to dermatologic health. By integrating evidence-based topical agents, procedures, and assessment metrics, skin fitness aims to extend \"skin span,\" enhance patient adherence, and position dermatology within the broader preventive and performance-based healthcare framework.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 1-2 Suppl 1","pages":"S10-S12"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prurigo Nodularis and the Pain Cascade: Understanding the Pathogenesis and Approach to Management.","authors":"Joshua Burshtein, Aaron Burshtein, Todd Schlesinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Prurigo nodularis (PN) is a chronic inflammatory dermatologic condition characterized by symmetrically distributed, intensely pruritic, hyperkeratotic nodules. This review aims to explore the role of the central and peripheral nervous systems in PN, focusing on the pain cascade pathway and its implications for novel therapeutic approaches.</p><p><strong>Methods: </strong>A review of the literature on PN and the pathophysiology of the pain cascade was performed. Original and review articles published before April 1, 2025, were evaluated for relevance.</p><p><strong>Results: </strong>The pathophysiology of PN involves repetitive scratching that leads to skin thickening and an exaggerated immune response, with key roles played by eosinophils, helper T (Th) cell 2 cytokines (interleukin [IL]-4, IL-13, IL-31), and neuroimmune interactions that perpetuate the itch-scratch cycle and the pain cascade. Management requires a multimodal approach including behavioral strategies, topical corticosteroids, intralesional therapies, and phototherapy. Systemic treatments, ranging from immunosuppressants and neuromodulators to targeted biologics, are often necessary due to the refractory nature of PN. Monoclonal antibodies such as dupilumab and nemolizumab, which target specific cytokine pathways, have significantly advanced treatment options. Ongoing trials with emerging agents emphasize the importance of immunomodulation in transforming PN care and guiding future therapies.</p><p><strong>Conclusion: </strong>PN is a chronic dermatologic condition that severely impacts quality of life. Emerging research into its pathophysiology indicates immune and neuronal dysregulation. Recent therapeutics have changed the standard of care for patients with PN. Continued future research into pathophysiology and the pain cascade can inform development of additional novel therapeutics.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 1","pages":"11-16"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}